Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind

Investors Await Additional Proof Points

 
• By Mandy Jackson
  
Biopharma stock valuations are beginning to recover, but cell and gene therapy firms are lagging (Shutterstock)

More from Financing

More from Scrip